BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 25893298)

  • 1. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
    He Y; Wu AC; Harrington BS; Davies CM; Wallace SJ; Adams MN; Palmer JS; Roche DK; Hollier BG; Westbrook TF; Hamidi H; Konecny GE; Winterhoff B; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Tinker AV; Gilks CB; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD
    Oncogene; 2016 Jan; 35(4):468-78. PubMed ID: 25893298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
    Harrington BS; He Y; Davies CM; Wallace SJ; Adams MN; Beaven EA; Roche DK; Kennedy C; Chetty NP; Crandon AJ; Flatley C; Oliveira NB; Shannon CM; deFazio A; Tinker AV; Gilks CB; Gabrielli B; Brennan DJ; Coward JI; Armes JE; Perrin LC; Hooper JD
    Br J Cancer; 2016 Feb; 114(4):417-26. PubMed ID: 26882065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration.
    Dong Y; He Y; de Boer L; Stack MS; Lumley JW; Clements JA; Hooper JD
    J Biol Chem; 2012 Mar; 287(13):9792-9803. PubMed ID: 22315226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of inside-out β1-integrin activation by CDCP1.
    Pollan SG; Huang F; Sperger JM; Lang JM; Morrissey C; Cress AE; Chu CY; Bhowmick NA; You S; Freeman MR; Spassov DS; Moasser MM; Carter WG; Satapathy SR; Shah K; Knudsen BS
    Oncogene; 2018 May; 37(21):2817-2836. PubMed ID: 29511352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface.
    Adams MN; Harrington BS; He Y; Davies CM; Wallace SJ; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD
    Oncogene; 2015 Mar; 34(11):1375-83. PubMed ID: 24681947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1.
    Fukuchi K; Steiniger SC; Deryugina E; Liu Y; Lowery CA; Gloeckner C; Zhou B; Kaufmann GF; Quigley JP; Janda KD
    Mol Pharm; 2010 Feb; 7(1):245-53. PubMed ID: 19916495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation.
    Miyazawa Y; Uekita T; Hiraoka N; Fujii S; Kosuge T; Kanai Y; Nojima Y; Sakai R
    Cancer Res; 2010 Jun; 70(12):5136-46. PubMed ID: 20501830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of autophagy by CUB domain-containing protein 1 signaling is essential for anchorage-independent survival of lung cancer cells.
    Uekita T; Fujii S; Miyazawa Y; Hashiguchi A; Abe H; Sakamoto M; Sakai R
    Cancer Sci; 2013 Jul; 104(7):865-70. PubMed ID: 23510015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of CDCP1 expression promotes invasiveness and poor prognosis in esophageal squamous cell carcinoma.
    Sawada G; Takahashi Y; Niida A; Shimamura T; Kurashige J; Matsumura T; Ueo H; Uchi R; Takano Y; Ueda M; Hirata H; Sakimura S; Shinden Y; Eguchi H; Sudo T; Sugimachi K; Miyano S; Doki Y; Mori M; Mimori K
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S640-7. PubMed ID: 24849519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIF-2α regulates CDCP1 to promote PKCδ-mediated migration in hepatocellular carcinoma.
    Cao M; Gao J; Zhou H; Huang J; You A; Guo Z; Fang F; Zhang W; Song T; Zhang T
    Tumour Biol; 2016 Feb; 37(2):1651-62. PubMed ID: 26307391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of CUB domain containing protein expression in endometrioid adenocarcinoma.
    Mamat S; Ikeda J; Enomoto T; Ueda Y; Rahadiani N; Tian T; Wang Y; Qiu Y; Kimura T; Aozasa K; Morii E
    Oncol Rep; 2010 May; 23(5):1221-7. PubMed ID: 20372833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation.
    Cui YH; Kim H; Lee M; Yi JM; Kim RK; Uddin N; Yoo KC; Kang JH; Choi MY; Cha HJ; Kwon OS; Bae IH; Kim MJ; Kaushik N; Lee SJ
    Oncogene; 2018 Oct; 37(43):5794-5809. PubMed ID: 29973690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients.
    Emerling BM; Benes CH; Poulogiannis G; Bell EL; Courtney K; Liu H; Choo-Wing R; Bellinger G; Tsukazawa KS; Brown V; Signoretti S; Soltoff SP; Cantley LC
    Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3483-8. PubMed ID: 23378636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.
    Sandercock AM; Rust S; Guillard S; Sachsenmeier KF; Holoweckyj N; Hay C; Flynn M; Huang Q; Yan K; Herpers B; Price LS; Soden J; Freeth J; Jermutus L; Hollingsworth R; Minter R
    Mol Cancer; 2015 Jul; 14():147. PubMed ID: 26227951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis.
    Liu H; Ong SE; Badu-Nkansah K; Schindler J; White FM; Hynes RO
    Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1379-84. PubMed ID: 21220330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration.
    Seidel J; Kunc K; Possinger K; Jehn C; Lüftner D
    Biochem Biophys Res Commun; 2011 Oct; 414(1):226-32. PubMed ID: 21945930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer.
    Alajati A; Guccini I; Pinton S; Garcia-Escudero R; Bernasocchi T; Sarti M; Montani E; Rinaldi A; Montemurro F; Catapano C; Bertoni F; Alimonti A
    Cell Rep; 2015 Apr; 11(4):564-76. PubMed ID: 25892239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADAM9 enhances CDCP1 protein expression by suppressing miR-218 for lung tumor metastasis.
    Chiu KL; Kuo TT; Kuok QY; Lin YS; Hua CH; Lin CY; Su PY; Lai LC; Sher YP
    Sci Rep; 2015 Nov; 5():16426. PubMed ID: 26553452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases.
    Leroy C; Shen Q; Strande V; Meyer R; McLaughlin ME; Lezan E; Bentires-Alj M; Voshol H; Bonenfant D; Alex Gaither L
    Oncogene; 2015 Oct; 34(44):5593-8. PubMed ID: 25728678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stratum basale keratinocyte expression of the cell-surface glycoprotein CDCP1 during epidermogenesis and its role in keratinocyte migration.
    McGovern JA; Heinemann JR; Burke LJ; Dawson R; Parker TJ; Upton Z; Hooper JD; Manton KJ
    Br J Dermatol; 2013 Mar; 168(3):496-503. PubMed ID: 23121233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.